StemCells Inc. (STEM) Given New $1.20 Price Target at S&P Equity Research
StemCells Inc. (NASDAQ:STEM) had its price target hoisted by S&P Equity Research from $1.07 to $1.20 in a research note issued on Thursday. S&P Equity Research’s price target suggests a potential downside of 1.64% from the stock’s current price.
StemCells (NASDAQ:STEM) traded down 9.02% on Thursday, reaching $1.11. The company’s stock had a trading volume of 1,124,331 shares. StemCells has a 52 week low of $0.33 and a 52 week high of $7.56. The stock’s market capitalization is $13.33 million. The firm has a 50 day moving average price of $1.46 and a 200 day moving average price of $1.63.
StemCells Company Profile
StemCells, Inc (StemCells) is engaged in the research, development and commercialization of stem cell therapeutics. The Company is focused on developing and commercializing stem and progenitor cells as the basis for therapeutics and therapies. Its lead product development program is its central nervous system (CNS) program, in which it is developing applications for HuCNS-SC cells, its human neural platform technology.
Receive News & Stock Ratings for StemCells Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for StemCells Inc. and related stocks with our FREE daily email newsletter.